Search research articles
Contact Us
Filters
Showing results (141-150 of 257) with videos related to
Page
of 26
Sort By:
Antimicrobial Agents and Chemotherapy
|
December 21, 2011
Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010
Rodrigo E Mendes, Leah N Woosley, David J Farrell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
October 10, 2019
Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens
Rodrigo E Mendes, Paul R Rhomberg, Troy Lister, et al.
Diagnostic Microbiology and Infectious Disease
|
March 22, 2013
Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria
Ronald N Jones, Michael L Wilson, Melvin P Weinstein, et al.
Diagnostic Microbiology and Infectious Disease
|
March 13, 2013
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011
Robert K Flamm, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy
|
December 11, 2013
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States
Rodrigo E Mendes, Robert K Flamm, Patricia A Hogan, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
January 30, 2019
<i>In Vitro</i> Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> (2014-2015) in the United States
Michael A Pfaller, Helio S Sader, Paul R Rhomberg, et al.
Antimicrobial Agents and Chemotherapy
|
March 23, 2016
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
March 26, 2016
Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates
Rodrigo E Mendes, Patricia A Hogan, Ronald N Jones, et al.
Journal of Global Antimicrobial Resistance
|
July 24, 2017
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)
Leonard R Duncan, Helio S Sader, Jennifer I Smart, et al.
Antimicrobial Agents and Chemotherapy
|
October 29, 2014
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Page
of 26
Search research articles
Search
Showing results (141-150 of 257) with videos related to
Sort By:
Page
of 26
Antimicrobial Agents and Chemotherapy
|
December 21, 2011
Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010
Rodrigo E Mendes, Leah N Woosley, David J Farrell, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
October 10, 2019
Evaluation of Antimicrobial Effects of a New Polymyxin Molecule (SPR741) When Tested in Combination with a Series of β-Lactam Agents Against a Challenge Set of Gram-Negative Pathogens
Rodrigo E Mendes, Paul R Rhomberg, Troy Lister, et al.
Diagnostic Microbiology and Infectious Disease
|
March 22, 2013
Contemporary potencies of minocycline and tetracycline HCL tested against Gram-positive pathogens: SENTRY Program results using CLSI and EUCAST breakpoint criteria
Ronald N Jones, Michael L Wilson, Melvin P Weinstein, et al.
Diagnostic Microbiology and Infectious Disease
|
March 13, 2013
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011
Robert K Flamm, Rodrigo E Mendes, James E Ross, et al.
Antimicrobial Agents and Chemotherapy
|
December 11, 2013
Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States
Rodrigo E Mendes, Robert K Flamm, Patricia A Hogan, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
January 30, 2019
<i>In Vitro</i> Activity of Tedizolid in Comparison with Other Oral and Intravenous Agents Against a Collection of Community-Acquired Methicillin-Resistant <i>Staphylococcus aureus</i> (2014-2015) in the United States
Michael A Pfaller, Helio S Sader, Paul R Rhomberg, et al.
Antimicrobial Agents and Chemotherapy
|
March 23, 2016
Oritavancin Activity Tested against Molecularly Characterized Staphylococci and Enterococci Displaying Elevated Linezolid MIC Results
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
The Journal of Antimicrobial Chemotherapy
|
March 26, 2016
Surveillance for linezolid resistance via the Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) programme (2014): evolving resistance mechanisms with stable susceptibility rates
Rodrigo E Mendes, Patricia A Hogan, Ronald N Jones, et al.
Journal of Global Antimicrobial Resistance
|
July 24, 2017
Telavancin activity in vitro tested against a worldwide collection of Gram-positive clinical isolates (2014)
Leonard R Duncan, Helio S Sader, Jennifer I Smart, et al.
Antimicrobial Agents and Chemotherapy
|
October 29, 2014
Baseline activity of telavancin against Gram-positive clinical isolates responsible for documented infections in U.S. hospitals (2011-2012) as determined by the revised susceptibility testing method
Rodrigo E Mendes, David J Farrell, Helio S Sader, et al.
Page
of 26